#$%^&*AU2013201071A120130314.pdf#####ABSTRACT The present invention provides a medicinal aerosol suspension formulation for MDI administration, comprising: a) micronized 2-agonist b) micronized corticosteroid c) a sub-therapeutic quantity of a moisture-scavenger excipient and d) a HFA propellant wherein (a), (b) and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant.1/2 Figure 1: Aerodynamic particle size distribution of Fluticasone/formoterol formulation batches 2028/1 0AI01 (solid symbols) and 7 (clear symbols) as determined by ACI at 28.3 L/min flow rate, 4 L volume, n=5. Upper graph: fluticasone results lower graph: formoterol results. T30.0 - 25.0 ..... 20.0 ii.... .. ... .. .. ................ ..... ..... .. . . S2 E E E E E E E E C 0 0 0 0 0 10.0 - -R I V V V V V V V (D 0 j 0, 0) a) a .0 00 .................... .. . . . 6 5 E E E E E E S E 0 8 0 0 2 2 2 PE~ 0 0) Ln) ~ ~ (D V V V V V V V o oo9 ot o0 o0 I 0 N 9v (D M C tM CD) M) 5
